Published in Clin Cancer Res on September 04, 2013
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res (2014) 1.03
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. J Natl Cancer Inst (2015) 0.92
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology (2017) 0.75
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03
Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis (2007) 1.01
Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer (2004) 1.00
Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem (2008) 0.98
Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther (2006) 0.98
Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97
Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol (2010) 0.96
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res (2012) 0.94
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol (2007) 0.93
Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther (2010) 0.92
Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer (2011) 0.92
Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther (2005) 0.91
Interleukin-15 in gene therapy of cancer. Curr Gene Ther (2013) 0.91
The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer (2007) 0.90
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol (2011) 0.89
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med (2012) 0.89
CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol (2012) 0.88
Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clin Cancer Res (2009) 0.87
Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy (2009) 0.87
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res (2003) 0.86
Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur J Immunol (2010) 0.86
Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. J Invest Dermatol (2013) 0.85
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One (2012) 0.85
T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol (2013) 0.84
Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer (2010) 0.83
CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells. FASEB J (2012) 0.83
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Cell tracking using multimodal imaging. Contrast Media Mol Imaging (2013) 0.83
Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine (2005) 0.82
Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS One (2011) 0.82
Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J Hepatol (2009) 0.82
Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol (2007) 0.81
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med (2012) 0.80
Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp Hematol (2002) 0.80
LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms. Genes Cancer (2011) 0.80
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther (2007) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One (2011) 0.79
Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother (2010) 0.79
Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res (2012) 0.78
Awareness and understanding of cancer immunotherapy in Europe. Hum Vaccin Immunother (2014) 0.77
The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. Immunotherapy (2012) 0.77
Protein pE120R of African swine fever virus is post-translationally acetylated as revealed by post-source decay MALDI mass spectrometry. Virus Genes (2006) 0.77
Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther (2005) 0.77
Biologic therapy of liver tumors. Surg Clin North Am (2004) 0.76
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol (2002) 0.76
Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity. Arch Immunol Ther Exp (Warsz) (2002) 0.75
Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain. J Transl Med (2014) 0.75
Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. Oncoimmunology (2012) 0.75
High-density lipoproteins delivering interleukin-15. Oncoimmunology (2013) 0.75
MAGE antigens: therapeutic targets in hepatocellular carcinoma? J Hepatol (2004) 0.75
[Role of interleukin-12 in cancer immunotherapy]. Medicina (B Aires) (2004) 0.75
International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010. Cancer Immunol Immunother (2011) 0.75
Immunology and gene therapy: shoulder to shoulder into the fray. Mol Ther (2010) 0.75